加速期与急变期骨髓增殖性肿瘤的突变图谱影响患者结局
该回顾性分析纳入本机构治疗的122例加速期或急变期骨髓增殖性肿瘤患者(加速期14例,急变期108例),采用54基因靶向测序描述突变谱并与临床结局关联。JAK2V617F最常见(55%),TP53突变与较短总生存相关(HR 1.89,P=0.03);多变量分析中TP53突变、≥4个突变、低白蛋白、外周血原始细胞增高、≥3种细胞遗传学异常及最佳支持治疗与较短生存相关。
要点
- JAK2V617F见于55%的加速期或急变期骨髓增殖性肿瘤患者,CALR 13%,MPL 6%,三阴性26%。
- TP53是唯一与较短总生存相关的单基因突变(HR 1.89,P=0.03)。
- 强化治疗与非强化治疗生存无差异,强化治疗获益仅限于能接受移植的患者。
核心结论
- 突变数据有助于理解加速期或急变期骨髓增殖性肿瘤患者中可能从当前治疗选择中获益的人群。
研究设计与样本
- 本机构所有接受治疗的加速期或急变期骨髓增殖性肿瘤患者的回顾性分析,共122例(加速期14例,急变期108例),采用54基因靶向测序。
- 44例接受强化治疗,27例接受非强化治疗,51例接受最佳支持治疗。
主要发现
- 最常见突变为JAK2V617F,见于55%的患者;CALR见于13%,MPL见于6%;32例(26%)为三阴性。
- 其他常见突变基因为ASXL1(30%)、TET2(25%)、SRSF2(22%)、RUNX1(20%)和TP53(17%)。
- 分别有15%、13%、25%和46%的患者携带1、2、3和≥4个突变基因。
- 接受强化治疗与接受非强化治疗的患者生存无差异,强化治疗的获益仅限于能够接受移植的患者。
- TP53是唯一与较短总生存相关的单基因突变(风险比1.89;P=0.03)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a paucity of data regarding the impact of mutations on outcomes in accelerated-phase (AP) and blast-phase (BP) myeloproliferative neoplasms (MPNs). Moreover, it is unknown whether mutational status affects survival, as seen in chronic-phase MPNs. Therefore, we performed a retrospective analysis of all patients treated at our institution with AP/BP MPNs (N = 122; AP = 14; BP = 108) to comprehensively describe the mutational profile and correlate with clinical outcomes. Targeted sequencing with a 54-gene panel was performed. Forty-four patients were treated with intensive therapy, 27 with nonintensive therapy, and 51 with best supportive care (BSC). The most common mutation was JAK2V617F, occurring in 55% of subjects; CALR was found in 13% of patients and MPL in 6%. Thirty-two (26%) patients were triple negative. Other frequently mutated genes were ASXL1 (30%), TET2 (25%), SRSF2 (22%), RUNX1 (20%), and TP53 (17%). Mutations in 1, 2, 3, and ≥4 genes were seen in 15%, 13%, 25%, and 46% of patients, respectively. There was no difference in survival between patients treated with intensive vs nonintensive therapy, and the benefit of intensive therapy was limited to patients who were able to undergo transplantation. TP53 was the only individual mutation to correlate with shorter overall survival (hazard ratio, 1.89; P = .03). In the multivariate analysis, mutated TP53, ≥4 mutations, low albumin, increased peripheral blood blasts, ≥3 cytogenetic abnormalities, and BSC were associated with shorter survival. In conclusion, mutational data enhance the understanding of patients with AP/BP MPN who are likely to benefit from current therapeutic options.
引用
- McNamara CJ, Panzarella T, Kennedy JA, et al. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Adv. 2018. PMID: 30327374. doi:10.1182/bloodadvances.2018021469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。